Journal article · 2025 · Open access

Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trial

Masaharu Masuda, Akihiro Sunaga, Nobuaki Tanaka, Tetsuya Watanabe, Hitoshi Minamiguchi, Yasuyuki Egami, Takafumi Oka, Tomoko Minamisaka, Takashi Kanda, Masato Okada, Masato Kawasaki, Yasuhiro Matsuda and 61 more

Nature Medicine, 31(5), 1661–1667 · Published 30 April 2025 · DOI 10.1038/s41591-025-03674-y

Open PDFView at the publisherCite this paper

In brief

“Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trial” is a 2025 journal article by Masaharu Masuda and 72 co-authors, published in Nature Medicine. OpenAlex counts 74 citations as of 22 November 2026, which puts it in the top 1% of works published in 2025 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Medicine.

Citations
74
Most cited in
2026 (57)
Field-weighted impact
35.61
References
32
Authors
73

Abstract

Low-voltage areas (LVAs) in the left atrium may promote atrial fibrillation (AF), but the efficacy of LVA ablation for preventing arrhythmia has not been determined. In the present study, we carried out a multicenter, randomized controlled trial (SUPPRESS-AF) to investigate the efficacy of LVA ablation in patients with persistent AF who had left atrial LVAs. Patients with persistent AF and left atrial LVAs that covered ≥5 cm 2 of the left atrial surface on a voltage map after pulmonary vein isolation (PVI) were randomized to undergo LVA ablation (PVI + LVA-ABL group) or not (PVI-alone group) in a 1:1 fashion. Recurrence of AF or atrial tachycardia (AT) was monitored using 24-h Holter electrocardiography (ECG) and twice-daily portable ECG recordings. The primary endpoint was freedom from AF or AT recurrence without antiarrhythmic drug use during 1 year of follow-up. Of 1,347 patients (1,003 males and 344 females) who underwent initial ablation for AF, patients with left atrial LVAs were assigned to the PVI + LVA-ABL ( n = 170) or the PVI-alone group ( n = 171). Although the PVI + LVA-ABL group demonstrated a numerically higher rate of freedom from AF or AT recurrence compared with the PVI-alone group (61% (95% confidence interval (CI) = 53–68%) versus 50% (95% CI = 42–57%)), this difference did not reach statistical significance ( P for log(rank) test = 0.127). There was no difference in the procedure-related serious adverse events between the two groups (1.7% versus 1.8%, P < 0.0001). In conclusion, LVA ablation in addition to PVI did not significantly reduce 1-year AF or AT recurrence in patients with persistent AF with left atrial LVAs. Future studies are needed to identify patients who may receive greater benefit from LVA ablation.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Masuda, M., Sunaga, A., Tanaka, N., Watanabe, T., Minamiguchi, H., Egami, Y., Oka, T., Minamisaka, T., Kanda, T., Okada, M., Kawasaki, M., Matsuda, Y., Tanaka, K., Yamada, T., Hikoso, S., Dohi, T., Inoue, K., Sotomi, Y., Sakata, Y., . . . Ohashi, T. (2025). Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trial. Nature Medicine, 31(5), 1661–1667. https://doi.org/10.1038/s41591-025-03674-y

MLA 9

Masuda, Masaharu, et al. “Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trial.” Nature Medicine, vol. 31, no. 5, 2025, pp. 1661–1667. https://doi.org/10.1038/s41591-025-03674-y.

Chicago

Masuda, Masaharu, Akihiro Sunaga, Nobuaki Tanaka, Tetsuya Watanabe, Hitoshi Minamiguchi, Yasuyuki Egami, Takafumi Oka, et al. 2025. “Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trial.” Nature Medicine 31 (5): 1661–1667. https://doi.org/10.1038/s41591-025-03674-y.

Harvard

Masuda, M. et al. (2025) ‘Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trial’, Nature Medicine, 31(5), pp. 1661–1667. doi:10.1038/s41591-025-03674-y.

IEEE

M. Masuda et al., “Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trial,” Nature Medicine, vol. 31, no. 5, pp. 1661–1667, 2025, doi: 10.1038/s41591-025-03674-y.

BibTeX

@article{masuda2025voltage,
  title     = {{Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trial}},
  author    = {Masuda, Masaharu and Sunaga, Akihiro and Tanaka, Nobuaki and Watanabe, Tetsuya and Minamiguchi, Hitoshi and Egami, Yasuyuki and Oka, Takafumi and Minamisaka, Tomoko and Kanda, Takashi and Okada, Masato and Kawasaki, Masato and Matsuda, Yasuhiro and Tanaka, Koji and Yamada, Tomomi and Hikoso, Shungo and Dohi, Tomoharu and Inoue, Koichi and Sotomi, Yohei and Sakata, Yasushi and the OCVC-SUPPRESS-AF investigators and Uematsu, Hiroyuki and Tsujimura, Takuya and Ooka, Hirotaka and Kudo, Satoshi and Matsuoka, Yuki and Nakatani, Daisaku and Okada, Katsuki and Kida, Hirota and Sakamoto, Daisuke and Kitamura, Tetsuhisa and others},
  journal   = {Nature Medicine},
  year      = {2025},
  volume    = {31},
  number    = {5},
  pages     = {1661--1667},
  doi       = {10.1038/s41591-025-03674-y},
  url       = {https://doi.org/10.1038/s41591-025-03674-y}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes

  • low-voltage areas
  • left atrium
  • pulmonary vein isolation
  • catheter ablation
  • atrial tachycardia
  • arrhythmia recurrence

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Masuda, M., Sunaga, A., Tanaka, N., Watanabe, T., Minamiguchi, H., Egami, Y., Oka, T., Minamisaka, T., Kanda, T., Okada, M., Kawasaki, M., Matsuda, Y., Tanaka, K., Yamada, T., Hikoso, S., Dohi, T., Inoue, K., Sotomi, Y., Sakata, Y., . . . Ohashi, T. (2025). Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trial. Nature Medicine, 31(5), 1661–1667. https://doi.org/10.1038/s41591-025-03674-y

How many times has this paper been cited?

74 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Masaharu Masuda, Akihiro Sunaga, Nobuaki Tanaka, Tetsuya Watanabe, Hitoshi Minamiguchi, Yasuyuki Egami, Takafumi Oka, Tomoko Minamisaka, Takashi Kanda, Masato Okada, Masato Kawasaki, Yasuhiro Matsuda and 61 more.

What is the DOI of this paper?

10.1038/s41591-025-03674-y, permanently at https://doi.org/10.1038/s41591-025-03674-y. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.